Advertisement

Topics

Latest "HDT Engineered Technologies" News Stories

21:39 EST 16th December 2018 | BioPortfolio

Here are the most relevant search results for "HDT Engineered Technologies" found in our extensive news archives from over 250 global news sources.

More Information about HDT Engineered Technologies on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about HDT Engineered Technologies for you to read. Along with our medical data and news we also list HDT Engineered Technologies Clinical Trials, which are updated daily. BioPortfolio also has a large database of HDT Engineered Technologies Companies for you to search.

Showing "Engineered Technologies" News Articles 1–25 of 5,500+

Sunday 16th December 2018

Bionow Announces Appointment of 4 New Directors

Bionow, the award-winning specialist business development and services company serving the life sciences sector in the North England, has announced the appointment of four new Directors. Bionow is delighted that Emma Banks, Kris Matykiewicz, Martino Picardo and Mark Hollingworth will be joining the Bionow Board with effect from 22nd March 2018. Emma Banks is CEO of North East based Datatrial, and ...


SIGA Technologies Inc SIGA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12102018] Prices from USD $250

SummarySiga Technologies Inc Siga a subsidiary of MacAndrews and Forbes Holdings Inc, is a health security service provider. The company develops and commercialise solutions for serious unmet medical needs and bio threats. It offers antiviral drug to treat smallpox disease. Siga offers product such as TPOXX. The company's USAN Tecovirimat is combined with smallpox vaccines to prevent disease and r...

Emisphere Technologies Inc EMIS Strategic SWOT Analysis Review [Report Updated: 05122018] Prices from USD $125

Emisphere Technologies Inc EMIS Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company's key employees, key competitors and major products and services.This uptotheminute company report will help you to formulate strategies to drive y...


Neurosigma Inc Product Pipeline Analysis, 2018 Update [Report Updated: 06122018] Prices from USD $750

SummaryNeurosigma Inc Neurosigma is a life science company that develops and commercializes trigeminal nerve stimulation technologies for neurologic and psychiatric disorders. The company offers treatments for epilepsy, depression, attention deficit hyperactivity disorder, and posttraumatic stress disorders. It also conducts preclinical research and development, and phase clinical trials. The comp...

Ligand Pharmaceuticals Inc LGND Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummaryLigand Pharmaceuticals Inc Ligand develops and acquires technologies that help in discovery and development of medicines. The company employs research technologies including nuclear receptor assays, formulation science, high throughput computer screening, antibody discovery technologies and liver targeted prodrug technologies to assist companies in securing prescription drug approvals. It p...

Saturday 15th December 2018

Week in Review: Two China Biopharmas Raise $1.4 Billion in Hong Kong IPOs

Deals and Financings  WuXi AppTec, China's largest CRO/CMO, completed its $967 million IPO in Hong Kong and finished its first trading day at the offer price; Shanghai Junshi Bioscience will raise up to $414 million in a Hong Kong IPO to support its antibody portfolio, including the first PD-1 candidate with an accepted China NDA; WuXi Biologics formed a $450 million partnership with Oxford ...

Peanut Allergy: Opportunity Analysis and Forecasts to 2027 [Report Updated: 28062018] Prices from USD $9346

Peanut Allergy: Opportunity Analysis and Forecasts to 2027SummaryPeanut allergy is defined as a harmful health effect resulting from a specific and reproducible immune response following the ingestion of peanuts. While exposure to dietary antigens within the gastrointestinal tract normally leads to oral tolerance, in certain individuals this mechanism fails. This results in sensitization and subse...

Robotics in Healthcare Thematic Research [Report Updated: 31102018] Prices from USD $1658

Robotics in Healthcare Thematic ResearchSummaryIncreasingly, robots are seen as a solution to many of the structural problems facing the developed worldsagging productivity, aging populations, swelling healthcare budgets, and even epidemics of depression and an increasingly fragmented society. Of course, not everyone shares this view, and many are worried about the impact of robotics on employmen...

QuantuMDx Group Ltd Medical Equipment Deals and Alliances Profile [Report Updated: 06122018] Prices from USD $250

SummaryQuantuMDx Group Ltd QuantuMDx is a developer of sciences tools and diagnostics products. The company's products include QPOC, a handheld DNA analyzer that provides an accurate molecular diagnostic results. It develops assays for diagnosis and drug susceptibility testing of infectious diseases, and companion diagnostics assays and tumour profiling. QuantuMDx also develops technologies such a...

Covalon Technologies Ltd COV Medical Equipment Deals and Alliances Profile [Report Updated: 06122018] Prices from USD $250

SummaryCovalon Technologies Ltd Covalon is a researcher, developer and commercializer of medical products and healthcare technologies. The company offers advanced wound care, infection prevention and perioperative care products. Its wound care products include collagen matrix dressing, collagen matrix dressing with silver, wound contact layer, nonadherent foam dressing and superabsorbent dressing,...

Saving the Seas: New Technologies to Protect the Ocean

The ocean covers more than 70 percent of our planet’s surface. The Pacific alone is more than 60 million square miles. And yet, technologists are often focused on their home turf, populating roads with Ubers, equipping cities with wireless access points, and covering the land with cellular base stations. Thus far, the 321,003,271 cubic miles […]

Friday 14th December 2018

Novanta Inc NOVT Medical Equipment Deals and Alliances Profile [Report Updated: 07092018] Prices from USD $250

SummaryNovanta Inc Novanta, formerly GSI Group Inc is a medical device company that manufactures and markets precision photonics, motion control components and subsystems. The company provides laser products, medical technologies, and precision motion products. It offers laser sources and beam delivery technologies for electronics, industrial, medical, and scientific applications. Novanta 's techn...

Cerveau Announces Singapore Test of Neuro PET Imaging Agent

Cerveau Technologies, a partnership between Beijing Sinotau Pharma and Enigma Biomedical of Toronto, will start a Singapore trial of its PET imaging agent for neurofibrillary tangles (NFTs) in the brain, the first Asia test of the agent. Cerveau develops diagnostics and technology for neurodegenerative disorders including Alzheimer's disease. It in-licensed global rights to the agent, MK-6240, fro...

Cellomics Gains Rights to Molecular Probes' Fluorescence Technologies, Products

Cellomics Inc. (Pittsburgh) has entered into an agreement with Molecular Probes Inc. (Eugene, OR) that grants Cellomics exclusive rights to key Molecular Probes fluorescence technologies and products for use in Cellomics' high content cell-based drug discovery technologies...

Fluidigm Announces Closing of Public Offering of 9,372,500 Shares of Common Stock Including Full Exercise of Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Dec. 14, 2018 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, today announced the closing of its previously announced underwritten public offering of 9,372,500 shares of its common stock. … Continue reading →

Novel Adeno-associated Virus Vectors Energizing Neuroscience, Recent Advances & Clinical Trial Analysis, 2018 report – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Novel Adeno-associated Virus Vectors Energizing Neuroscience” report has been added to ResearchAndMarkets.com’s offering. This edition of the Genetic Technology TOE provides insights across new gene therapy technologies enabling enhanced management of neurological disorders. The service encompasses the impact … Continue reading →...

Applied Genetic Technologies Corp AGTC Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 06122018] Prices from USD $250

SummaryApplied Genetic Technologies Corp AGTC is a pharmaceutical company that provides development of eye disease cures. The company develops treatments for patients that have diseases caused by broken genes. It offers products such as xlinked retinoschisis, achromatopsia, xlinked retinitis pigmentosa, alpha1 antitrypsin deficiency and macular degeneration, among others. AGTC's achromatopsia prov...

Edmonton to Host Clinical Trial for Nova Oculus Medical Device that Could Help Improve Vision for AMD Sufferers

Health Canada approves study for pioneering treatment EDMONTON, Alberta (PRWEB) December 14, 2018 NOVA OCULUS PARTNERS, LLC, and its Canadian partner, the Eye Machine Canada Inc., have been given the green light to immediately begin a clinical patient trial in Edmonton using their pioneering technology for treating Age-Related Macular Degeneration (AMD). The medical devices bureau of Health Canad...

Medtronic PLC Strategy, SWOT and Corporate Finance Report [Report Updated: 23102018] Prices from USD $175

Medtronic PLC Strategy, SWOT and Corporate Finance ReportSummaryMedtronic PLC Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360 view of the company.Key HighlightsMedtronic PLC Medtronic or 'the company' is ...

Dentsply Sirona, Inc. Strategy, SWOT and Corporate Finance Report [Report Updated: 21112018] Prices from USD $175

Dentsply Sirona, Inc. Strategy, SWOT and Corporate Finance ReportSummaryDentsply Sirona, Inc. Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360 view of the company.Key HighlightsDentsply Sirona, Inc. Dentsp...

Study: New technologies leading to less traditional store checkouts

According to a study by Z

bioLIVE China 2019 to be Newly Upgraded to Lead the Development of Bio-Pharma Technology in Asia

SHANGHAI, Dec. 14, 2018 /PRNewswire/ -- The bio-pharma industry has entered the new stage of rapid development in recent years with the continuous development of cutting-edge biological technology and the emergence and marketing of new targeted drugs and cell therapies. From the perspective of global market size, sales of the global biotech drugs are expected to account for more than one third of ...

Take the Lead to Deploy Emerging Technologies for Improved Outcomes

Brad Wilson, Industry Voice, former CEO of Blue Cross and Blue Shield of North CarolinaEmerging technologies, such as artificial intelligence (AI), have the potential to accelerate the shift to value-based care and improve the healthcare system in material ways.

Generex Biotechnology Partner Regentys Corporation Receives European Patent Approval for ECMH™ for Treatment of Ulcerative Colitis

Regentys Extracellular Matrix Hydrogel (ECMH™) Advances Regenerative Medicine Approach for Inflammatory Bowel Diseases Generex Biotechnology Corporation (OTCQB:GNBT) announced today that Regentys Corporation (formerly Asana Medical, Inc.), a clinical stage regenerative medicine company contracted to become a subsidiary of Generex, was granted Europea...

Driven by China Biopharm Industry, Cell Culture Market to Reach $6.2 Billion in 2022: Report

The global market for cell culture products for use in the research, development, and production of biotherapeutic drugs is forecast to reach $6.2 billion in 2022, according to Kalorama Information. NEW YORK (PRWEB) December 14, 2018 Key factors impacting market demand include healthy growth in the production of biopharmaceuticals, the increasing availability of biosimilar products, the continued...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks